Immunomodulatory interventions vs placebo
Immunomodulatory interventions may leads to higher adverse events of glucocorticoids and immunosuppressive drugs compared with placebo (low certainty).
- RR 1.161 study · 66 participantsLow
Immunomodulatory interventions may leads to higher adverse events of glucocorticoids and immunosuppressive drugs compared with placebo (low certainty).
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) compared with usual care (low certainty).
Antioxidant(s) showed no clear difference in adverse events ‐ Ectopic pregnancy№ of participants: 404(4 RCTs) compared with placebo or no treatment/standard treatment (low certainty).
The review found no eligible studies for this question.
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Probiotics used as adjuvants to conventional antifungal drugs showed no clear difference in rate of serious adverse events compared with conventional antifungal drugs (low certainty).
It is very uncertain whether vortioxetine changes drop‐out due to adverse events compared with SNRIs (very low certainty).
Vortioxetine probably leads to higher drop‐out due to adverse events compared with placebo (moderate certainty).
Antioxidant(s) showed no clear difference in adverse events ‐ Multiple pregnancy№ of participants: 1886(9 RCTs) compared with placebo or no treatment/standard treatment (low certainty).
Any cranberry product showed no clear difference in gastrointestinal adverse events compared with placebo or control (moderate certainty).
The intervention showed no clear difference in maternal serious adverse events (low certainty).
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
Hydrogel dressings showed no clear difference in adverse events (wound infection) compared with hydrogel dressings (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.